Education
About Us
Working with TipRanks
Follow Us
Eupraxia Pharmaceuticals (EPRX)
NASDAQ:EPRX
RESEARCH TOOLSreports
EPRX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.20 - $4.48
Previous CloseN/A
Volume2.60K
Average Volume (3M)18.39K
Market Cap
C$113.88M
Enterprise Value$156.59M
Total Cash (Recent Filing)C$1.16M
Total Debt (Recent Filing)C$11.94M
Price to Earnings (P/E)―
Beta1.09
Next Earnings
May 08, 2025EPS Estimate
-0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.76
Shares Outstanding35,849,354
10 Day Avg. Volume9,890
30 Day Avg. Volume18,394
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-3.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$12.14Price Target Upside315.74% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
Eupraxia Pharmaceuticals News
---
Options Prices
Currently, No data available
---
Ownership Overview
12.63% Insiders
3.94% Other Institutional Investors
83.43% Public Companies and
Individual Investors
EPRX FAQ
What was Eupraxia Pharmaceuticals’s price range in the past 12 months?
Eupraxia Pharmaceuticals lowest stock price was $2.20 and its highest was $4.48 in the past 12 months.
What is Eupraxia Pharmaceuticals’s market cap?
Eupraxia Pharmaceuticals’s market cap is C$113.88M.
When is Eupraxia Pharmaceuticals’s upcoming earnings report date?
Eupraxia Pharmaceuticals’s upcoming earnings report date is May 08, 2025 which is in 32 days.
How were Eupraxia Pharmaceuticals’s earnings last quarter?
Eupraxia Pharmaceuticals released its earnings results on Mar 20, 2025. The company reported -$0.215 earnings per share for the quarter, missing the consensus estimate of -$0.158 by -$0.057.
Is Eupraxia Pharmaceuticals overvalued?
According to Wall Street analysts Eupraxia Pharmaceuticals’s price is currently Undervalued.
Does Eupraxia Pharmaceuticals pay dividends?
Eupraxia Pharmaceuticals does not currently pay dividends.
What is Eupraxia Pharmaceuticals’s EPS estimate?
Eupraxia Pharmaceuticals’s EPS estimate is -0.18.
How many shares outstanding does Eupraxia Pharmaceuticals have?
Eupraxia Pharmaceuticals has 35,849,354 shares outstanding.
What happened to Eupraxia Pharmaceuticals’s price movement after its last earnings report?
Eupraxia Pharmaceuticals reported an EPS of -$0.215 in its last earnings report, missing expectations of -$0.158. Following the earnings report the stock price went down -2.251%.
Which hedge fund is a major shareholder of Eupraxia Pharmaceuticals?
Currently, no hedge funds are holding shares in EPRX
---
Eupraxia Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$12.14 (315.74% Upside)
$12.14 (315.74% Upside)
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
1.21%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-59.24%
Trailing 12-Months
Company Description
Eupraxia Pharmaceuticals
Eupraxia Pharmaceuticals Inc., a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector. The company's lead product candidate is EP-104IAR, which is in a Phase II clinical trial for the treatment of unmet medical needs and for pain relief for knee osteoarthritis, as well as under development for treating canine and equine osteoarthritis. Its products in development also include EP-201, an antibiotic for post-surgical site infections; and EP-105, an extended-release post-surgical anesthetic for post-surgical pain. In addition, the company develops product candidates for oncology. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012.Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.
---
EPRX Stock 12 Month Forecast
Average Price Target
$12.14
▲(315.74% Upside)
Technical Analysis
Best Analysts Covering EPRX
1 Year
1 Year Success Rate
0/1 ratings generated profit
1 Year Average Return
-2.30%
initiated a buy rating 5 months ago
Copying Brandon Folkes's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -2.30% per trade.
---